Europe
Three months after it won approval in type 2 diabetes, AstraZeneca’s Farxiga is eying potential regulatory win as a treatment in heart failure patients.
“Bavencio is the first immunotherapy to demonstrate in a clinical trial a statistically significant improvement in overall survival as a first-line treatment for patients with advanced urothelial carcinoma,” said Chris Boshoff, chief development officer, Oncology, Pfizer Global Product Development.
Antabio’s Pseudomonas Elastase Inhibitor (PEi) has the potential to significantly enhance the effectiveness of current CF therapy
Testicular cancer can be prevented from coming back using half the amount of chemotherapy that is currently used, a new clinical trial has shown.
Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019.
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
Researchers recently identified molecules that can inhibit DNA methylation and kill even the most resistant of the malaria parasites, Plasmodium falciparum.
In the My$99Insulin Program, patients can buy up to three vials or two packs of FlexPen/FlexTouch/PenFill pens of any combination of Novo Nordisk insulins for $99.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
With a new year upon us, some analysts are already picking potential winners in the market for 2020. One of those companies could be Denmark-based Novo Nordisk.
PRESS RELEASES